Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium propionate plus nab-paclitaxel, gemcitabine, and PD-1 inhibitor for first-line advanced pancreatic cancer
ChiCTR2500110471Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium propionate in pancreatic cancer (PC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate. Started Oct 2025; status: recruiting.
02
Drugs
sodium propionate
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500110471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110471.